Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04667741
Other study ID # 12869
Secondary ID
Status Completed
Phase
First received
Last updated
Start date October 1, 2020
Est. completion date July 1, 2022

Study information

Verified date September 2022
Source Istanbul Demiroglu Bilim University
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Patients undergoing hemodialysis (HD) can experience symptoms such as lassitude, pain, muscle cramps, nausea, vomiting, constipation, diarrhea, rash, skin dryness, sleep disorders, and emotional and sexual problems after the treatment.


Description:

Many chronic HD patients do not feel well after the treatment sessions and need some time to recover. This recovery time is defined as the time required to recover from the feelings of lassitude and fatigue. The patients are limited in their daily living activities at home and at work during this period and a significant amount of time is therefore required to go back to normal life.


Recruitment information / eligibility

Status Completed
Enrollment 294
Est. completion date July 1, 2022
Est. primary completion date April 1, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - 18 years or older - Being on HD for 4 hours a day on 3 days per week for at least 6 months - No communication problem - Volunteering to participate to the study Exclusion Criteria: - Younger than 18 years - Shorter being on HD for 4 hours a day on 3 days per week for at least 6 months - Have communication problem - Not volunteering to participate to the study

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Post-dialysis recovery group
Before the hemodialysis session, the patients were asked by the investigators how long it took them to recover from a dialysis session, taking the last treatment month into account.

Locations

Country Name City State
Turkey Demiroglu Bilim University Istanbul

Sponsors (1)

Lead Sponsor Collaborator
Istanbul Demiroglu Bilim University

Country where clinical trial is conducted

Turkey, 

References & Publications (3)

Alvarez L, Brown D, Hu D, Chertow GM, Vassalotti JA, Prichard S. Intradialytic Symptoms and Recovery Time in Patients on Thrice-Weekly In-Center Hemodialysis: A Cross-sectional Online Survey. Kidney Med. 2019 Dec 20;2(2):125-130. doi: 10.1016/j.xkme.2019.10.010. eCollection 2020 Mar-Apr. — View Citation

Bossola M, Di Stasio E, Monteburini T, Parodi E, Ippoliti F, Cenerelli S, Santarelli S, Nebiolo PE, Sirolli V, Bonomini M, Antocicco M, Zuccalà G, Laudisio A. Recovery Time after Hemodialysis Is Inversely Associated with the Ultrafiltration Rate. Blood Purif. 2019;47(1-3):45-51. doi: 10.1159/000492919. Epub 2018 Sep 19. — View Citation

Umeukeje EM, Cavanaugh KL. Intradialytic Symptoms and Recovery Time: Thinking 'Outside the Box' to Improve Patients' Dialysis Experience. Kidney Med. 2020 Feb 28;2(2):98-101. doi: 10.1016/j.xkme.2020.02.001. eCollection 2020 Mar-Apr. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Post-dialysis Recovery Time Before the hemodialysis session, the patients were asked by the investigators how long it took them to recover from a dialysis session, taking the last treatment month into account. up to 4 weeks
Primary Anxiety at one month It will be assessed with Hospital Anxiety and Depression Scale. This scale, which has a two-factor structure is comprised of 14 items. Seven of these items assess the anxiety status and the remaining seven assess depression.
Each item is scored on a four-point scale. Total score ranges between 0 and 21 for anxiety and depression. Scores between 0 and 7 indicate normal emotional status.
up to 4 weeks
Primary Depression at one month It will be assessed with Hospital Anxiety and Depression Scale. This scale, which has a two-factor structure is comprised of 14 items. Seven of these items assess the anxiety status and the remaining seven assess depression.
Each item is scored on a four-point scale. Total score ranges between 0 and 21 for anxiety and depression. Scores between 0 and 7 indicate normal emotional status.
up to 4 weeks
Primary Rate of Headache at one month The patients will tell the living of headache to the investigators at the end of the one month. The answer will be "yes" or "no". up to 4 weeks
Primary Rate of dry mouth at one month The patients will tell the living of dry mouth to the investigators at the end of the one month. The answer will be "yes" or "no". up to 4 weeks
Primary Rate of trouble falling asleep at one month The patients will tell the living of trouble falling asleep to the investigators at the end of the one month. The answer will be "yes" or "no". up to 4 weeks
Primary Hemodialysis Sessions Features Before and after the hemodialysis sessions, the patients were asked by investigators about dialysate bicarbonate concentration in mmol/L up to 4 weeks
Primary Biochemical variables at one month After one month urea reduction rate (%) were aken from the patients' medical record up to 4 weeks
See also
  Status Clinical Trial Phase
Not yet recruiting NCT05031013 - Trace Elements Concentration in Dialysis
Not yet recruiting NCT03090828 - Economic Evaluation of an Education Platform for Patients With End-stage Renal Disease N/A
Completed NCT01685372 - Immunogenicity of Fluzone High Dose in Immunocompromised Children and Young Adults Phase 2
Active, not recruiting NCT01394770 - Aliskiren or Amlodipine in Hypertensive Hemodialysed Patients Phase 4
Completed NCT00506441 - A Phase 3, Randomized, Double Blind, Placebo-Controlled, Multi-Center, Withdrawal Study of MCI-196 in CKD on Dialysis With Hyperphosphatemia Phase 3
Completed NCT00537979 - Efficacy and Safety of 6 Months Treatment With Paricalcitol Injection or Oral in Patients With Secondary Hyperparathyroidism on Dialysis Phase 4
Completed NCT05415969 - CKD-aP Among Adults on Dialysis in Switzerland
Recruiting NCT04024007 - Determination of Citrate Clearance Used in Regional Anticoagulation of Continuous Venous Hemofiltration Circuits
Completed NCT03772171 - Estimate for Dietary Intakes and Hemodialysis Patients
Recruiting NCT02586402 - Safety & Efficacy of Pegolsihematide for Treatment of Anemia in Participants on Dialysis Phase 2
Active, not recruiting NCT01693263 - Outcome of BCF Access in Hemodialysis Patients
Completed NCT01421771 - Blood Pressure in Dialysis Patients N/A
Active, not recruiting NCT01065389 - Resistance Training in Intradialysis Patients Phase 2
Completed NCT00544492 - Study of Pain, Anxiety and Complications Related to Cannulation of Arteriovenous (AV) Fistula in Chronic Hemodialysis Patients Phase 4
Completed NCT03910426 - Prognostic Determinants of Survival and Quality of Life in Prevalent End-stage Kidney Disease Patients
Completed NCT04565522 - Transmission of COVID-19 Virus Among Patients and Staff in Dialysis Centers
Completed NCT04655989 - A Study to Demonstrate the Safety and Effectiveness of the NIKKISO DBB-EXA ES Hemodialysis Delivery System N/A
Completed NCT05125848 - Clinical Evaluation of the CM-1500 During Hemodialysis N/A
Completed NCT04633915 - Antibody Response in Hemodialysis and Non-dialysis Patients Diagnosed With COVID-19.
Completed NCT00767897 - The Impact of the Human Papilloma Virus in Pediatric Chronic Kidney Disease, Dialysis, and Transplant Patients